Glooko touted data today from a six-month pilot program that evaluated the company’s remote diabetes management technology for people with Type II diabetes.
The pilot, which spanned from April until October of 2016, involved 50 Type II diabetes patients from San Diego, Calif.-based Sharp Rees-Stealy Medical Group. The medical group evaluated patient engagement, A1c levels, LDL, microalbumin and blood pressure throughout the course of the study.
Steve MacMillan took over as CEO of Hologic in 2013, drawing on his experience at medtech titans like Stryker and Johnson & Johnson. Since then, Hologic has grown into a $3 billion business.
At DeviceTalks Boston, MacMillan will provide exclusive insights into the Massachusetts-based company and its evolving definition of women's healthcare. You don't want to miss it!
Use code WOMENSHEALTH to save an additional 10%.